Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14130986 | 0.83 | KDM4E (0.44) | KDM4EGAAMAPTMAPK1 | |
| SCHEMBL7025149 | 0.81 | MAPT (0.38) | KDM4EGAAMAPTPDE4AKCNH2 | |
| SCHEMBL7019829 | 0.78 | LATS1 (0.36) | KDM4EGAAMAPTKCNH2MAPK1 | |
| SCHEMBL3356207 | 0.76 | MAPK1 (0.36) | KDM4EMAPTMAPK1 | |
| SCHEMBL1959338 | 0.72 | AS3MT (0.40) | — | |
| SCHEMBL3355418 | 0.71 | LATS1 (0.36) | KDM4EGAAMAPTKCNH2MAPK1 | |
| SCHEMBL14143504 | 0.66 | MAPT (0.36) | KDM4EGAAMAPTMAPK1 | |
| SCHEMBL13914465 | 0.65 | MAPT (0.37) | KDM4EGAAMAPTKCNH2 | |
| SCHEMBL3355530 | 0.65 | NPY1R (0.36) | KDM4EMAPTKCNH2 | |
| SCHEMBL3357439 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949646-B2 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES CO. (US) | 2005-09-27 | — | — | US | disclosed |
| US-20050107421-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-05-19 | — | — | US | disclosed |
| US-6638944-B2 | Have urea containing substituent at 1-position; induce biosynthesis of cytokines such as interferon and tumor necrosis factor, exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107421-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | KDM4E 4437/4885GAA 538/4885MAPT 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.